Latest Researches in the 3rd issue of Cancer Biology & Medicine


   As a peer-reviewed open-access journal, Cancer Biology & Medicine is quarterly published by China Anti-Cancer Association and Tianjin Medical University Cancer Institute and Hospital. It focuses on translational cancer research, dedicating to narrowing the gap between bench and bedside. The journal is now indexed in Science Citation Index Expanded (SCIE, IF=4.248) and MEDLINE. All full texts are available at http://www.ncbi.nlm.nih.gov/pmc/journals/2000/

 

   In this issue, Prof. Ning Zhang et al. from Peking University First Hospital (China) commented on the role of midlobular zone 2 hepatocytes in regeneration under homeostatic and injured liver conditions. Prof. Joseph P. Balthasar et al. from University at Buffalo (USA) summarized the antibody therapies in solid tumors and the strategies on enhancing monoclonal antibody uptake and distribution in a review.

 

   Among the original articles, Modified R-CODOX-M/IVAC chemotherapy regimens in Chinese patients with untreated sporadic Burkitt lymphoma authored by Prof. Tongyu Lin et al. (Sichuan Cancer Hospital & Institute, Sun Yat-sen University Cancer Center) is specially recommended. They concluded that the modified R-CODOX-M/IVAC chemotherapy regimen was effective for sporadic Burkitt lymphoma in the Chinese population, with a lower toxicity than standard regimens. We hope this issue will greatly benefit your research and clinical practice. Welcome to submit your work to Cancer Biology & Medicine.


A breakthrough in liver regeneration for treatment of liver cancer

Hao Xu, Yisheng Pan, Ning Zhang
Cancer Biol Med. 2021 Aug 15; 18(3): 631–634.

Current research on circular RNAs and their potential clinical implications in breast cancer

Diya Liu, Lin Fang
Cancer Biol Med. 2021 Aug 15; 18(3): 635–648.

Strategies to enhance monoclonal antibody uptake and distribution in solid tumors

Brandon M. Bordeau, Joseph P. Balthasar
Cancer Biol Med. 2021 Aug 15; 18(3): 649–664.

FGFR/RACK1 interacts with MDM2, promotes P53 degradation, and inhibits cell senescence in lung squamous cell carcinoma

Tao Chen, Fei Wang, Shupei Wei, Yingjie Nie, Xiaotao Zheng, Yu Deng, Xubin Zhu, Yuezhen Deng, Nanshan Zhong, Chengzhi Zhou
Cancer Biol Med. 2021 Aug 15; 18(3): 665–674.

LncRNA DPP10-AS1 promotes malignant processes through epigenetically activating its cognate gene DPP10 and predicts poor prognosis in lung cancer patients

Haihua Tian, Jinchang Pan, Shuai Fang, Chengwei Zhou, Hui Tian, Jinxian He, Weiyu Shen, Xiaodan Meng, Xiaofeng Jin, Zhaohui Gong
Cancer Biol Med. 2021 Aug 15; 18(3): 675–692.

Heat shock protein 90 promotes RNA helicase DDX5 accumulation and exacerbates hepatocellular carcinoma by inhibiting autophagy

Ting Zhang, Xinrui Yang, Wanping Xu, Jing Wang, Dawei Wu, Zhixian Hong, Shengxian Yuan, Zhen Zeng, Xiaodong Jia, Shanshan Lu, Rifaat Safadi, Sen Han, Zhihong Yang, Leonard M. Neckers, Suthat Liangpunsakul, Weiping Zhou, Yinying Lu
Cancer Biol Med. 2021 Aug 15; 18(3): 693–704.

NEDD9 promotes cancer stemness by recruiting myeloid-derived suppressor cells via CXCL8 in esophageal squamous cell carcinoma

Dongli Yue, Shasha Liu, Tengfei Zhang, Yong Wang, Guohui Qin, Xinfeng Chen, Huanyu Zhang, Dong Wang, Lan Huang, Feng Wang, Liping Wang, Song Zhao, Yi Zhang
Cancer Biol Med. 2021 Aug 15; 18(3): 705–720.

Complement C3a activates osteoclasts by regulating the PI3K/PDK1/SGK3 pathway in patients with multiple myeloma

Fengjuan Jiang, Hui Liu, Fengping Peng, Zhaoyun Liu, Kai Ding, Jia Song, Lijuan Li, Jin Chen, Qing Shao, Siyang Yan, Kim De Veirman, Karin Vanderkerken, Rong Fu
Cancer Biol Med. 2021 Aug 15; 18(3): 721–733.

A novel recurrence-associated metabolic prognostic model for risk stratification and therapeutic response prediction in patients with stage I lung adenocarcinoma

Chengming Liu, Sihui Wang, Sufei Zheng, Xinfeng Wang, Jianbin Huang, Yuanyuan Lei, Shuangshuang Mao, Xiaoli Feng, Nan Sun, Jie He
Cancer Biol Med. 2021 Aug 15; 18(3): 734–749.

Raltitrexed as a synergistic hyperthermia chemotherapy drug screened in patient-derived colorectal cancer organoids

Lisi Zeng, Quanxing Liao, Haoran Zhao, Shengwei Jiang, Xianzi Yang, Hongsheng Tang, Qingjun He, Xiansheng Yang, Shuxian Fang, Jinfu He, Weiwen Cui, Laiqiang Huang, Shaohua Ma, Shuzhong Cui
Cancer Biol Med. 2021 Aug 15; 18(3): 750–762.

Development and validation of a risk model for noninvasive detection of cancer in oral potentially malignant disorders using DNA image cytometry

Chenxi Li, Yongmei Zhou, Yiwen Deng, Xuemin Shen, Linjun Shi, Wei Liu
Cancer Biol Med. 2021 Aug 15; 18(3): 763–771.

VHH212 nanobody targeting the hypoxia-inducible factor 1α suppresses angiogenesis and potentiates gemcitabine therapy in pancreatic cancer in vivo

Guangbo Kang, Min Hu, He Ren, Jiewen Wang, Xin Cheng, Ruowei Li, Bo Yuan, Yasmine Balan, Zixuan Bai, He Huang
Cancer Biol Med. 2021 Aug 15; 18(3): 772–787.

CD44v8-10 is a marker for malignant traits and a potential driver of bone metastasis in a subpopulation of prostate cancer cells

Rosaria A. Fontanella, Silvia Sideri, Chiara Di Stefano, Angiolina Catizone, Silvia Di Agostino, Daniela F. Angelini, Gisella Guerrera, Luca Battistini, Giulia Battafarano, Andrea Del Fattore, Antonio Francesco Campese, Fabrizio Padula, Paola De Cesaris, Antonio Filippini, Anna Riccioli
Cancer Biol Med. 2021 Aug 15; 18(3): 788–807.

Typing of biliary tumor thrombus influences the prognoses of patients with hepatocellular carcinoma

Juxian Sun, Jiayi Wu, Chang Liu, Jie Shi, Yonggang Wei, Jianyin Zhou, Zhibo Zhang, Wan Yee Lau, Maolin Yan, Shuqun Cheng
Cancer Biol Med. 2021 Aug 15; 18(3): 808–815.

Equivalent efficacy study of QL1101 and bevacizumab on untreated advanced non-squamous non-small cell lung cancer patients: a phase 3 randomized, double-blind clinical trial

Tianqing Chu, Jun Lu, Minghong Bi, Helong Zhang, Wu Zhuang, Yan Yu, Jianhua Shi, Zhendong Chen, Xiaochun Zhang, Qisen Guo, Quan Liu, Huijuan Wu, Jian Fang, Yi Hu, Xiuwen Wang, Cuicui Han, Kai Li, Baohui Han
Cancer Biol Med. 2021 Aug 15; 18(3): 816–824.

Identification of optimal contemporary antiemetic prophylaxis for doxorubicin-cyclophosphamide chemotherapy in Chinese cancer patients: post-hoc analysis of 3 prospective studies

Winnie Yeo, Leung Li, Thomas KH Lau, Kwai T Lai, Vicky TC Chan, Kwan H Wong, Christopher CH Yip, Elizabeth Pang, Maggie Cheung, Vivian Chan, Carol CH Kwok, Joyce JS Suen, Frankie KF Mo
Cancer Biol Med. 2021 Aug 15; 18(3): 825–832.

Modified R-CODOX-M/IVAC chemotherapy regimens in Chinese patients with untreated sporadic Burkitt lymphoma

Meiting Chen, Zhao Wang, Xiaojie Fang, Yuyi Yao, Quanguang Ren, Zegeng Chen, Ying Tian, Fei Pan, Xiaoqian Li, Zhiming Li, Qingqing Cai, He Huang, Tongyu Lin
Cancer Biol Med. 2021 Aug 15; 18(3): 833–840.

The combination of chidamide with the CHOEP regimen in previously untreated patients with peripheral T-cell lymphoma: a prospective, multicenter, single arm, phase 1b/2 study

Wei Zhang, Liping Su, Lihong Liu, Yuhuan Gao, Quanshun Wang, Hang Su, Yuhuan Song, Huilai Zhang, Jing Shen, Hongmei Jing, Shuye Wang, Xinan Cen, Hui Liu, Aichun Liu, Zengjun Li, Jianmin Luo, Jianxia He, Jingwen Wang, O. A. O’Connor, Daobin Zhou
Cancer Biol Med. 2021 Aug 15; 18(3): 841–848.

Anlotinib has good efficacy and low toxicity: a phase II study of anlotinib in pre-treated HER-2 negative metastatic breast cancer

Nanlin Hu, Yiran Si, Jian Yue, Tingting Sun, Xue Wang, Zhuqing Jia, Songlin Gao, Qiao Li, Yang Shao, Jiayu Wang, Yang Luo, Fei Ma, Binghe Xu, Peng Yuan
Cancer Biol Med. 2021 Aug 15; 18(3): 849–859.

Transcription factor-based gene therapy to treat glioblastoma through direct neuronal conversion

Xin Wang, Zifei Pei, Aasma Hossain, Yuting Bai, Gong Chen
Cancer Biol Med. 2021 Aug 15; 18(3): 860–874.

Phase II study of apatinib in combination with oral vinorelbine in heavily pretreated HER2-negative metastatic breast cancer and clinical implications of monitoring ctDNA

Anjie Zhu, Peng Yuan, Nanlin Hu, Mingzhou Li, Wenmiao Wang, Xue Wang, Jian Yue, Jiayu Wang, Yang Luo, Fei Ma, Pin Zhang, Qing Li, Binghe Xu, Shanbo Cao, Giuseppe Lippi, Yoichi Naito, Mohammed A. Osman, Gustavo N. Marta, Gianluca Franceschini, Armando Orlandi
Cancer Biol Med. 2021 Aug 15; 18(3): 875–887.

Epstein-Barr virus DNA loads in the peripheral blood cells predict the survival of locoregionally-advanced nasopharyngeal carcinoma patients

Yongqiao He, Dawei Yang, Ting Zhou, Wenqiong Xue, Jiangbo Zhang, Fangfang Li, Fang Wang, Tongmin Wang, Ziyi Wu, Ying Liao, Meiqi Zheng, Changmi Deng, Danhua Li, Yijing Jia, Leilei Yuan, Wenli Zhang, Weihua Jia
Cancer Biol Med. 2021 Aug 15; 18(3): 888–899.

Breast cancer incidence and mortality in women in China: temporal trends and projections to 2030

Shaoyuan Lei, Rongshou Zheng, Siwei Zhang, Ru Chen, Shaoming Wang, Kexin Sun, Hongmei Zeng, Wenqiang Wei, Jie He
Cancer Biol Med. 2021 Aug 15; 18(3): 900–909.

Efficacy of the new therapeutic approach in curing malignant neoplasms on the model of human glioblastoma

Evgeniya V. Dolgova, Oleg M. Andrushkevich, Polina E. Kisaretova, Anastasia S. Proskurina, Genrikh S. Ritter, Tatyana D. Dubatolova, Margarita V. Romanenko, Oleg S. Taranov, Yaroslav R. Efremov, Evgeniy L. Zavyalov, Alexandr V. Romaschenko, Sergey V. Mishinov, Svetlana S. Kirikovich, Evgeniy V. Levites, Ekaterina A. Potter, Alexandr A. Ostanin, Elena R. Chernykh, Stanislav Yu. Roshchin, Anatoliy V. Bervitskiy, Galina I. Moysak, Jamil A. Rzaev, Sergey S. Bogachev
Cancer Biol Med. 2021 Aug 15; 18(3): 910–930.